What a Trump FTC means for biotech and pharma dealmakingnews2024-12-16T18:48:14+00:00December 16th, 2024|Endpoints News|
Bristol Myers drops cell therapy pacts with Immatics, Century as part of portfolio reviewnews2024-12-16T11:45:07+00:00December 16th, 2024|Endpoints News|
FTC OKs Novo-Catalent deal, in major win for Novo Nordisk’s GLP-1 manufacturingnews2024-12-14T10:42:12+00:00December 14th, 2024|Endpoints News|
BeiGene licenses MAT2A cancer drug, matches with Ideaya’s combo plansnews2024-12-13T16:02:16+00:00December 13th, 2024|Endpoints News|
AbbVie makes another small I&I acquisition, buying Nimble for $200Mnews2024-12-13T14:41:24+00:00December 13th, 2024|Endpoints News|
Padlock shareholders sue Bristol Myers over milestone dispute after 2016 acquisitionnews2024-12-12T16:20:04+00:00December 12th, 2024|Endpoints News|
The Endpoints 100 Survey: Biotech industry braces for Trump 2.0news2024-12-11T12:00:55+00:00December 11th, 2024|Endpoints News|
Genetic medicine startups Chroma, Nvelop merge into nChromanews2024-12-11T12:00:50+00:00December 11th, 2024|Endpoints News|
Bayer exits Europe pact with Moberg for nail fungus drug after Phase 3 failnews2024-12-11T11:53:46+00:00December 11th, 2024|Endpoints News|
Walgreens in talks to sell to private equity — reportnews2024-12-10T18:23:25+00:00December 10th, 2024|Endpoints News|
